Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline

Neuropsychopharmacology

Volumn 25, Issue 1, 2001, Pages 131-138

  Rush, A John ^a   Trivedi, Madhukar H ^a   Carmody, Thomas J ^a   Donahue, Rafe M J ^b   Houser, Trisha L ^b   Bolden Watson, Carolyn ^b   Batey, Sharyn R ^b   Ascher, John A ^b   Metz, Alan ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Anxiolysis; Bupropion SR; Major depressive disorder; Pretreatment anxiety; Retrospective analysis; Sertraline

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGED; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME;

ADULT; AGED; ANXIETY; BUPROPION; DEPRESSIVE DISORDER, MAJOR; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 0035017807     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00249-9     Document Type: Article

References (32)

1. Practice guidelines for major depressive disorder in adults
2. Side effects of antidepressant drugs
3. Follow-up and family study of anxious depression
4. Sexual dysfunction associated with the treatment of depression: A placebo-controlled comparison of bupropion sustained release and sertraline treatment
5. A placebo-controlled comparison of the antidepressant and sexual functioning effects of bupropion sustained release and sertraline
6. Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo
7. The detection and consequences of anxiety in clinical depression
8. Double-blind comparison of bupropion and fluoxetine in depressed outpatients
9. SSRIs in anxious-agitated depression: A post-hoc analysis of 279 patients
10. Obsessive-compulsive disorder: Diagnosis and treatment
11. The assessment of anxiety states by rating
12. A rating scale for depression
13. Development of a rating scale for primary depressive illness
14. Sertraline approved for posttraumatic stress disorder
15. Anxious and nonanxious depression
16. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients
17. Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication
18. Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression
19. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients
20. Does pretreatment anxiety predict response to either bupropion SR or sertraline?
21. Anxiolysis associated with antidepressant response to bupropion sustained release or sertraline
22. Evaluation of sexual functioning in depressed outpatients: A double-blind comparison of sustained-release bupropion and sertraline treatment
23. Current concepts in the treatment of panic disorder
24. Should anxiety and insomnia influence antidepressant selection: A randomized comparison of fluoxetine and imipramine
25. Fluoxetine tenth anniversary update: The progress continues
26. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: A comparative trial of fluoxetine versus imipramine
27. Prognostic factors determining response to antidepressant drugs in psychiatric out-patients and general practice
28. Bupropion SR versus paroxetine for the treatment of depression in the elderly